Sale of 100% of the issued share capital of Lyramid to Pleiades; Minimum consideration amount of US$10 million consisting of equity in Pleiades, together with the potential for upfront cash #ROQ #Biotech

The sale of Lyramid validates our strategy to acquire, develop and then to realise value through licensing and trade-sale transactions. This strategy is particularly important in the UK, where private company valuations typically exceed those of UK public biotech entities #ROQ

🎥 Our CEO Ajan Reginald talks with Stephen Gunnion from @proactive_UK on the transformational proposed sale of our Midkine portfolio to Pleiades Pharma Ltd #ROQ #Midkine #biotech youtu.be/siSIreDVYmc

The proposed Midkine sale provides US$10m upfront sale value, whilst retaining potential for significant upside from holding equity in Pleiades Pharma Ltd - a private company developing a portfolio of clinical and pre-clinical assets led by industry veteran Caroline Fortier

Great to see coverage of #ROQ in the MailOnline Money on Monday: dailymail.co.uk/money/markets/…

Coiled Tx is a clinical stage oncology company and is a spin-out of A2A Pharma managed by CPS Capital. Coiled Tx holds the exclusive worldwide rights to AO-252, a novel, brain-penetrant small molecule inhibitor designed to disrupt TACC3 protein-protein interactions. Visit their

Coiled Tx’s lead program is AO-252, a meticulously designed small molecule inhibitor of TACC3. AO-252 specifically targets and disrupts the critical protein-protein interactions of TACC3. TACC3 is a protein over-expressed in multiple cancer cells and has important roles in DNA

📽️Our Chairman Stephen West details the many compelling reasons why the acquisition of Coiled Tx is transformational and beneficial for the shareholders of both Roquefort Therapeutics and Coiled Tx #ROQ #COILEDTX #A2APHARMA #AO252 #STAT6

Coiled Tx is the second spin-out from A2A Pharma. Biomea Fusion was the first spin-out that listed on Nasdaq in 2021 with a market cap of US$464m. Post-IPO Biomea’s market capitalisation reached a peak of over US$1 billion. In this second spin-out A2A Pharma will retain

The AO-252 program has advanced through pre-clinical development and IND approval and has commenced Phase I trials in the USA (trials ID: NCT06136884). Initial results are very encouraging with the drug showing very good safety and significant signs of efficacy, responses and

Coiled Tx have confirmed interest in the Roquefort Therapeutics’ STAT-6 siRNA program and its potential in autoimmune diseases. Post-merger, the aim is to progress the STAT-6 program through IND into Phase I clinical trials

Underpinning Roquefort Tx’s transaction with A2A Pharma is the commitment from A2A Pharma and its investors to provide the majority of the funding requirement over the next 2 years - with an investment of £6 million into the new enlarged entity, to be renamed Coiled Therapeutics

Coiled Tx is enrolling further patients for its active Phase I trial for AO-252 for TP53 mutated ovarian, endometrial and triple-negative breast cancers. An amendment has been filed to expand the market of AO-252 into all solid tumours

Based on Coiled Tx’s target patients' biomarket population, AO-252 could potentially be used to help as many as 350,000 cancer patients across multiple indications in the USA and European Union. Accordingly, if trials are successful, Coiled Tx has potential to be first move in a

📽️ Our Chairman Stephen West, alongside Edward Painter and Sridhar Vempati, Chairman and Chief Strategy Officer respectively of A2A Pharma will host a live interactive presentation on the Engage Investor platform on Monday, 29 September 2025 at 4pm BST. The objective of the

📢 Event announcement 📢 On Monday next week Roquefort Therapeutics PLC are hosting an presentation on the acquisition of Coiled Therapeutics, followed by an interactive Q&A session for investors Register now 👇 engageinvestor.news/ROQ_IP_0925

The ambition is to grow the market cap of Coiled Tx significantly on AIM through positive clinical results and other newsflow and then list the company on Nasdaq – which is a well-trodden path for biotech companies. Recent success stories that have taken this path are Amryt

📢 Tomorrow at 4pm 📢 Don't miss tomorrow's investor presentation to find out more about Roquefort Therapeutics's acquisition of Coiled Therapeutics. This is your chance to find out more & ask your questions! Register now 👇 engageinvestor.news/ROQ_IP_0925

👇Join us today at 4pm BST for our interactive presentation on the Engage Investor platform